Видео с ютуба Durvalumab

FDA Approves Durvalumab / Imfinzi for Resectable NSCLC Non-Small Cell Lung Cancer

Durvalumab: the new standard of care for NSCLC?

AEGEAN Trial: Perioperative Durvalumab for NSCLC - OncTalk Lung 2023

The impact of durvalumab on the SCLC treatment landscape

Perioperative Durvalumab in Bladder Cancer | NEJM

Trial of durvalumab for bladder cancer

Double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in NSCLC

Durvalumab + FLOT Yields Significantly Improved EFS in Gastric/GEJ Cancer in MATTERHORN Trial

Durvalumab - Imfinzi - All You Need to Know in 2 Minutes.

The Use of Durvalumab in Locally Advanced NSCLC

The Mechanism of Action of Durvalumab in the Treatment of Urothelial Bladder Cancer

Real-world outcomes of durvalumab ± tremelimumab in uHCC

Safety Profile of Durvalumab in Locally Advanced NSCLC

Tremelimumab and durvalumab therapy in lung cancer

Results from the PACIFIC study: durvalumab with chemoradiation for the treatment of NSCLC

Durvalumab after chemoradiotherapy improves overall survival in lung cancer patients

Neoadjuvant Durvalumab Shows Benefit in Triple-Negative Breast Cancer

Gastric Cancer Immunotherapy: Matterhorn Trial Durvalumab Results

Immune checkpoint inhibitors and their role in MM: pembrolizumab and durvalumab

DUTRENEO: durvalumab and tremelimumab vs chemo

Durvalumab: Avance en Inmunoterapia para Cáncer de Pulmón y Urotelial

Durvalumab & olaparib as maintenance in patients with MMR-proficient advanced endometrial cancer

Durvalumab (Imfinzi): How It Works, Benefits, and Side Effects Explained

ADRIATIC: patterns of disease progression with durvalumab in LS-SCLC

A video summary of the HIMALAYA study PLSP: Tremelimumab and Durvalumab for Unresectable HCC